Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine: interim guidance, 17 March 2021
Download
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting on 15 March 2021.
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest.
The guidance is based on the evidence summarized in the Background document on Janssen Ad26.COV2.S (COVID-19) vaccine and the Background paper on COVID-19 disease and vaccines.
